Document:

Exhibit 10.22

 

SPONSORED RESEARCH CONTRACT

 

THIS CONTRACT, effective the 16th
day of November, 2018 (hereinafter the “Effective Date”), is entered into by and between Baylor College of Medicine
(hereinafter “Baylor”) and Marker Therapeutics, Inc., a Delaware corporation, with principal offices located at 3200
Southwest Freeway Suite 2240, Houston, TX 77027 (hereinafter “Sponsor”), governing research to be conducted at Baylor
in the laboratory of Dr. Juan Vera (hereinafter “Principal Investigator”).

 

The parties agree as follows:

 

WHEREAS the Sponsor is interested in scientific
research related to the manufacturing of T-cells; and

 

WHEREAS Baylor has on its staff certain
scientists and technicians who possess unique knowledge and experience in substantive fields relating to such research; and

 

WHEREAS Baylor and Marker Therapeutics,
Inc., entered into a license agreement dated March 16, 2018 (“License”); and

 

WHEREAS the proposed research is intended,
to advance the development of the technology licensed by way of the License; and

 

WHEREAS Marker Therapeutics, Inc., changed
its name to Marker Cell Therapy, Inc., merged into Taplmmune, Inc., a Nevada corporation and Taplmmune, Inc. changed its name to
Marker Therapeutics, Inc. and reincorporated in Delaware; and

 

WHEREAS the Sponsor is willing to fund such research by Baylor.

 

NOW, THEREFORE, in consideration of the
premises and the mutual covenants and conditions hereinafter recited, the parties do hereby agree as follows:

 

	1.	Definitions

 

For purposes of this Contract, the following definitions
apply:

 

		1.1	“Affiliate(s)” shall mean any corporation or business entity which is controlled by,
controls, or is under common control of the Sponsor at the time of execution of this Contract. For this purpose, the meaning of
the word “control” shall include, without limitation, direct or indirect ownership of more than fitly percent (50%)
of the voting shares of such corporation, or fifty percent (50%) of the ownership interests in such other business entity.

 

    	 	 	 

    
CONFIDENTIAL TREATMENT REQUESTED BY MARKER THERAPEUTICS, INC. 
 
Portions herein identified by [***] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

    

 

		1.2	“Contract Period” shall mean the period commencing on the Effective Date of this Contract
and terminating on the fourth anniversary of the Effective Date. This Contract may be extended for an additional term by the mutual
written consent of the duly authorized representatives of Baylor and the Sponsor.

 

		1.3	“FDA” shall mean the United States Food and
Drug Administration.

 

		1.4	“Project Research” shall mean research pertaining to T-cell manufacturing as described
more fully in Exhibit A (which is incorporated herein by reference and made part of this Contract) or such modifications of Exhibit
A as may be mutually agreed upon in writing by duly authorized representatives of Baylor and the Sponsor.

 

		1.5	“Project Funds” shall mean those funds paid by the Sponsor to Baylor for the Project
Research in accordance with this Contract. Project Funds are detailed in Exhibit A “Budget”. Baylor and Sponsor have
negotiated the budgets for years I and 2 of this Agreement. The budgets for years 3 and 4 will be negotiated by Baylor and Sponsor
during the final six months of year 2. The Budget is inclusive of all indirect and overhead costs.

 

		1.6	“Project Team” shall mean the Principal Investigator and the research technicians under
the Principal Investigator's direction and control who are supported in whole or in part by the Project Funds.

 

	2.	Research

 

		2.1	Conduct of Project Research. During the Contract Period, the Project Team shall conduct
Project Research on behalf of the Sponsor.

 

		2.2	Meetings. During the Contract Period, the Principal Investigator and representatives
of the Sponsor shall meet from time to time to discuss the planning and progress of the Project Research.

 

		2.3	Reporting Obligations. Baylor shall advise the Sponsor of the results of the Project
Research and, at least once every six (6) months during the Contract Period, provide the Sponsor with written progress reports
concerning the Project Research. A final written report setting forth the results achieved under and pursuant to the Project Research
shall be submitted by Baylor to the Sponsor within ninety (90) days of termination of the research which is the subject of this
Contract. Such final report shall include: a complete summary of the research carried out and detailed experimental protocols of
the research performed in the course of the Project Research.

 

    	 	 	 

    
CONFIDENTIAL TREATMENT REQUESTED BY MARKER THERAPEUTICS, INC. 
 
Portions herein identified by [***] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

    

 

		2.4	Obligation to Provide Data. Baylor shall, throughout the term of this Contract, provide
to the Sponsor copies of all data and other information generated by or on behalf of the Project Team pursuant to this Contract
including, without limitation, all raw data obtained as a result of studies conducted in the course of Project Research and all
experimental procedures developed under the Project Research in sufficient written detail to permit the Sponsor's personnel to
employ such procedures in their own research.

 

		2.5	Compliance with Applicable Laws. All studies done in connection with the Project
Research shall be carried out in strict compliance with any applicable federal, state, or local laws, regulations, or guidelines
governing the conduct of such research.

 

		2.6	Project Team Personnel Changes. Baylor shall promptly advise the Sponsor in respect
to any changes in the personnel comprising the Project Team. If, for any reason, the Principal Investigator ceases to be associated
with Baylor, or otherwise becomes unavailable to work on the Project Research, a qualified replacement scientist at Baylor shall
be mutually appointed by Baylor and the Sponsor to be the Principal Investigator, or, at the Sponsor's sole option, this Contract
shall be terminated on thirty (30) days written notice.

 

	3.	Payments

 

		3.1	Payment Terms. With respect to the years 1 and 2 budgets, the Sponsor shall pay Baylor
the Project Funds amount of two hundred fifty six thousand two hundred seventy two Dollars ($256,272.00) in the following manner:

 

		(a)	on or before the Effective Date, the Sponsor shall pay Baylor the sum or ($76,882.00) Dollars:

 

		(b)	One hundred fifty three thousand seven hundred sixty four dollars ($153,764.00) shall be paid in
equal monthly installments on or before the first day of each month for the duration of the Contract Period.

 

		(c)	A final payment that includes all outstanding payments due will be sent by the Sponsor to Baylor
within thirty (30) days of receipt by the Sponsor of the final written report, as set forth in Section 2.3.

 

		(d)	With respect to the years 3 and 4 budgets, Sponsor shall pay the Project Funds for those years
on a similar schedule as that for the payments set forth above for years 1 and 2.

 

    	 	 	 

    
CONFIDENTIAL TREATMENT REQUESTED BY MARKER THERAPEUTICS, INC. 
 
Portions herein identified by [***] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

    

 

		3.2	Late Payments. In the event that any payment due hereunder is not made when due,
the payment shall accrue interest beginning on the first day of the month following the date when such payment is due, calculated
at the annual rate of the sum of (a) [***REDACTED***] percent ([***REDACTED***]%) plus (b)
the prime interest rate quoted by Citibank. N.A., New York, New York, on the date such payment is due, or on the date payment
is made, whichever is higher, the interest being compounded on the last day of each calendar month, provided that in no event shall
said annual rate exceed the maximum legal interest rate for corporations. Such payment when made shall be accompanied by all interest
so accrued. Said interest and the payment and acceptance thereof shall not negate or waive the right of Baylor to any other remedy,
legal or equitable, to which Baylor may be entitled because of the delinquency of the payment.

 

		3.3	Direction of Payments

 

Payments under the terms of this
Contract shall be made by check payable to:

  

	 	Name on check:
	Baylor College of Medicine
	 	Tax ID #:	[***REDACTED***]
	 	 	Grants and Contracts Dept.
	 	 	P.O. Box 301207
	 	 	Dallas, Texas 75303-1207

 

	4.	Non-Disclosure Agreement and Publications

 

		4.1	Scope of Confidentiality. Nothing in this Contract shall be construed to limit the
freedom of the Principal Investigator, physicians, research scientists, or other individuals conducting the Project Research, whether
paid under this Contract or otherwise, to engage in similar research performed independently under other grants, contracts, or
agreements with parties other than the Sponsor. Baylor, the Principal Investigator, and the Sponsor agree to use reasonable efforts
to prevent disclosure of information under and pursuant to this Contract which is designated in writing as being “CONFIDENTIAL”.

 

		4.2	Confidentiality Obligations. Baylor and the Sponsor further agree that, except as
provided in Section 4.3, 4.4 and 5.1 below, they will not use, except in furtherance of this Contract, and not disclose orally,
by written publication, or otherwise, any Project Research results except that such information may be disclosed insofar as such
disclosure is necessary to allow either Baylor or the Sponsor, as the case may be, (i) to defend itself against litigation, (ii)
to file and prosecute patent applications on any invention conceived or reduced to practice under the Project Research, or (iii)
to comply with judicial decree or government action. Notwithstanding the above, such obligation of confidentiality shall not apply
to information that at the time of disclosure:

 

    	 	 	 

    
CONFIDENTIAL TREATMENT REQUESTED BY MARKER THERAPEUTICS, INC. 
 
Portions herein identified by [***] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

    

 

		(a)	is in the public domain;

 

		(c)	has come into the public domain through no fault of Baylor;
was known to the receiving party prior to its disclosure by the disclosing party;

 

		(d)	is disclosed by a third party not under an obligation of non-disclosure;

 

		(e)	is required by law or legal process to be disclosed; or

 

		(f)	written permission for disclosure has been granted to the disclosing party by Baylor or the Sponsor,
as the case may be.

 

Additionally, Baylor may use
Project Research results in non-commercial research, so long as such non-commercial research is not made available to a commercial
third party.

 

		4.3	Publication Procedures. In the exercise of the rights of academic freedom of an educational
institution and its faculty, Baylor, the Principal Investigator, and the Project Team shall have the right to publish in scientific
or other journals, or to present at professional conferences or other meetings, the results of the Project Research conducted under
this Contract. In order to permit the Sponsor the opportunity to request protection of patent and proprietary rights relating to
the Project Research, a copy of each proposed publication shall be provided to the Sponsor thirty (30) days in advance of submission
for publication to permit the Sponsor time to review the subject matter of such publication. Requests for protection of patent
and proprietary rights shall be made to Baylor in writing within thirty (30) days of receipt of the proposed publication. Upon
such request, Baylor shall make reasonable efforts to secure patent protection as per Section 5.3. Any final proposed publication
provided to the Sponsor shall be considered as acceptable for submission for publication unless the Sponsor notifies Baylor and
the Principal Investigator within thirty (30) days of receipt of the proposed publication. The Sponsor shall also receive final
drafts of any proposed publication and the Sponsor shall be named in the publication as the sponsor of the Project Research or,
as the case may be, the licensee of such technology. The right to review publications as set forth herein shall extend only to
the work product of the Principal Investigator and the Project Team pursuant to the Project Research and not to the work product
of other research conducted in the laboratories of the Principal Investigator, or member of the Project Team, or in the laboratories
of other researchers at Baylor.

 

		4.4	Sponsor Sharing of Confidential Information. Sponsor may share Project Research results
with potential collaborators, and/or investors as needed, provided potential collaborators, and/or investors are under obligations
of confidentiality similar to those hereunder. Upon the earliest of (a) publication by Baylor per term 4.3 above, or (b) 18 months
have passed from completion of the Project Research hereunder, Sponsor may share the Project Research results for any purpose.

 

    	 	 	 

    
CONFIDENTIAL TREATMENT REQUESTED BY MARKER THERAPEUTICS, INC. 
 
Portions herein identified by [***] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

    

 

	5.	Ownership and Patents

 

		5.1	Ownership. Baylor shall have sole and exclusive ownership rights to any invention
of a product, device, process, or method, whether patentable or unpatentable (an “Invention”) arising out of the Project
Research subject to the right of the Sponsor to take an exclusive, or non-exclusive, fee-bearing, royalty-bearing license to the
Invention, as set forth in Section 5.2 below. Notwithstanding the foregoing, Inventions arising out of the Project Research hereunder,
which directly relate to the technology licensed to Sponsor under the License, and which were funded by the Sponsor, shall be incorporated
by amendment into the License.

 

		5.2	Right of First Review. Baylor grants to the Sponsor the right of first review with
respect to any Invention, discovered from the performance of the Project Research, under the following the terms:

 

		(a)	The Sponsor shall comply with the terms of non-disclosure, as set forth in Section 4 of this Contract.

 

		(b)	Baylor shall notify the Sponsor, in writing, of the Invention and provide the Sponsor with sufficient
detail to evaluate the Invention.

 

		(c)	The Sponsor shall have forty-five (45) days after such notification to evaluate the Invention and
notify Baylor, in writing, that the Sponsor desires to license the Invention.

 

		(d)	Upon notification by the Sponsor of its desire to acquire rights to the Invention, the Sponsor
and Baylor shall negotiate, in good faith, for a period not to exceed sixty (60) days, unless extended by mutual written agreement
of Baylor and the Sponsor, in an effort to arrive at terms and conditions satisfactory to Baylor and the Sponsor for the license
by the Sponsor of the Invention.

 

		(e)	If Baylor and the Sponsor do not reach such agreement within said sixty-day (60-day) period, or
if the Sponsor fails to notify Baylor within said forty-five-day (45-day) period, or if the Sponsor decides not to acquire the
rights to the Invention, Baylor shall be free to deal with the Invention as Baylor in its discretion may decide, and Baylor shall
have no further obligations to the Sponsor with respect to the Invention.

 

    	 	 	 

    
CONFIDENTIAL TREATMENT REQUESTED BY MARKER THERAPEUTICS, INC. 
 
Portions herein identified by [***] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

    

 

		(f)	The right of first review, as presented herein, shall terminate at the earlier of the (i) second
anniversary of the Effective Date or (ii) the termination of this Contract, but only if Baylor has previously provided Company
with written notification of all Inventions arising out of the Project Research. In the event Baylor has not provided such written
notification as to an Invention, Baylor will provide Sponsor with written notification and the provisions of this section 5.2 will
be carried out.

 

		5.3	Filing Obligations With respect to inventions which the Sponsor has elected to take
an exclusive, or non-exclusive, royalty-bearing license, as provided in Sections 5.1 and 5.2:

 

		(a)	Baylor shall be responsible for the preparation, filing, and prosecution of all patent applications
covering any Invention arising out of the Project Research. The Sponsor shall be responsible for all costs and fees associated
therewith from and after the Effective Date of such license and shall reimburse Baylor for such costs accrued prior to the Effective
Date of such license. Baylor shall seek and consider the advice and counsel of the Sponsor in such filing / prosecution of patent
applications. The Sponsor and its employees shall reasonably assist Baylor in the preparation, filing, and prosecution of such
patent applications;

 

		(b)	the Sponsor shall also have the responsibility for filing all applications which may be required
by health or regulatory authorities relating to the products arising from the Project Research including, without limitation, filing
a New Drug Application with the FDA. All costs and expenses associated with such filings shall be borne by the Sponsor. The Sponsor
shall own all right, title, and interest in any FDA or other regulatory approvals which are obtained by or on behalf of the Sponsor;
and,

 

		(c)	Baylor and its employees shall reasonably assist the Sponsor with respect to any filings which
may be required by appropriate health or regulatory authorities.

 

	6.	Termination

 

		6.1	Contract Period. This Contract shall remain in effect for the Contract Period unless
extended in accordance with the terms of this Contract, as outlined in Section 1.2.

 

		6.2	Termination for Default. In the event that either party shall be in default of any
of its obligations under this Contract and shall fail to remedy such default within sixty (60) days after receipt of written notice
thereof, the party not in default shall have the option
of canceling this Contract by giving thirty (30) days written notice of termination to the other party.

 

    	 	 	 

    CONFIDENTIAL TREATMENT REQUESTED BY MARKER THERAPEUTICS, INC.  
Portions herein identified by [***] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

    

  

		6.3	Effects of Termination; Survival. Termination of this Contract shall not affect the
rights and obligations of the parties, which shall have accrued prior to termination, including, without limitation, the confidentiality
obligations set forth in Section 4.1.

 

	7.	Indemnification

 

		7.1	Indemnity Obligation. The Sponsor agrees to defend, indemnify and hold harmless Baylor,
the Principal Investigator, Baylor's trustees, officers, agents, staff, employees, students, and faculty members, and its affiliated
hospitals (all such parties are hereinafter referred to collectively as the “Indemnified Parties”) from and against
any and all third party liability, claims, lawsuits, losses, demands, damages, costs, and expenses (including reasonable attorney's
fees and court costs), arising directly or indirectly out of the Project Research or the design, manufacture, sale or use of any
embodiment or manifestation of the Project Research regardless of whether any and all such liability, claims, lawsuits, losses,
demands, damages, costs, and expenses (including attorney's fees and court costs) arise in whole or in part from the negligence
of any of the Indemnified Parties. Notwithstanding the foregoing, the Sponsor will not be responsible for any liability, claims,
lawsuits, losses, demands, damages, costs, and expenses (including attorney's fees and court costs) which arise solely from:

 

		(i)	the gross negligence or intentional misconduct of Baylor or the Principal Investigator; and

 

		(ii)	actions by Baylor or the Principal Investigator in violation of applicable laws or regulations.

 

		7.2	Obligation to Defend. The Sponsor agrees to provide a diligent defense against any
and all liability, claims, lawsuits, losses, demands, damages, costs, and expenses (including attorney's fees and court costs),
brought against the Indemnified Parties with respect to the subject of the indemnity contained in Section 7.1, whether such claims
or actions are rightfully or wrongfully brought or filed.

 

		7.3	Indemnification Procedures. Any Indemnified Party wishing to be indemnified as provided
in Sections 7.1 and 7.2 shall:

 

		(a)	promptly after receipt of notice of any and all liability, claims, lawsuits losses, demands,
                                                             damages, costs, and expenses, or after the commencement of any action, suit, or proceeding giving rise to the right of
indemnification, notify the Sponsor, in writing, of said liability, claims, lawsuits, losses, demands, damages, costs, and expenses
and send to the Sponsor a copy of all papers served on the Indemnified Party; the Indemnified Party's failure to notify the Sponsor
will not relieve the Sponsor from any liability to the Indemnified Party;

 

    	 	 	 

    CONFIDENTIAL TREATMENT REQUESTED BY MARKER THERAPEUTICS, INC.  
Portions herein identified by [***] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

    

  

		(b)	permit the Sponsor to retain counsel of its choosing to represent the Indemnified Party (but in
the event that the Sponsor does not select counsel to represent the Indemnified Party within ten (10) days of notification of Sponsor
per section 7.3(a), the Indemnified Party may select its own counsel, the fees and all costs of which counsel will be borne by
the Sponsor); and

 

		(c)	allow the Sponsor to retain exclusive control of any such liability, claims, lawsuits, losses,
demands, damages, costs, and expenses, including the right to make any settlement, except that the Sponsor will not have the right
to make any settlement or take any other action which would be deemed to confess wrongdoing by any of the Indemnified Parties or
could reasonably be expected to have a negative effect on the reputation of one of the Indemnified Parties, without the prior written
consent of Baylor and the Indemnified Party involved.

 

	8.	Insurance

 

Insurance
Coverage Limits. During the term of this Contract, the Sponsor shall maintain in full force and effect a policy or policies
of:

 

		(i)	general liability insurance with limits of not less than $5,000,000 per occurrence and $5,000,000
annual aggregate; and

 

		(ii)	products liability insurance with limits of not less than $5,000,000 per occurrence and $5,000,000
annual aggregate.

 

Such policies
shall name Baylor, the Principal Investigator, Baylor's trustees, officers, agents, staff, employees, students, and faculty members,
and its affiliated hospitals as additional insureds. Such coverage(s) shall be purchased from a carrier or carriers deemed acceptable
to Baylor and certificates of insurance evidencing the coverage(s) maintained will be provided.

 

	10.	Independent Contractors

 

The Sponsor
and Baylor shall at all times act as independent parties and nothing contained in this Contract shall be construed or implied to
create an agency or partnership. Neither party shall
have the authority to contract or incur expenses on behalf of the other except as may be expressly authorized by collateral agreements.
The Principal Investigator and members of the Project Team shall not be deemed to be employees of the Sponsor.

 

    	 	 	 

    CONFIDENTIAL TREATMENT REQUESTED BY MARKER THERAPEUTICS, INC.  
Portions herein identified by [***] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

    

  

	11.	Use of Institution Name/Public Statements

 

		11.1	The Sponsor agrees that it will not at any time during or following termination of this Contract
use the name of Baylor or any other names, insignia, symbol(s), or logotypes associated with Baylor or any variant or variants
thereof or the names of the Principal Investigator or any other Baylor faculty member or employee orally or in any literature,
advertising, or other materials without the prior written consent of Baylor, which consent may be withheld at Baylor's sole discretion.
Notwithstanding the foregoing, the Sponsor shall be permitted to state orally and in writing the fact that the Project Research
is being conducted at Baylor under the direction of the Principal Investigator.

 

		11.2	Baylor agrees to make no public presentations about the Project Research outside of appropriate
scientific meetings, to issue no news releases about the Project Research, and neither party shall make use of the other's name
in any form of public information without the written permission of the other party.

 

	12.	Choice of Law

 

Any disputes or claims arising
under this Contract shall be governed by the laws of the State of Texas, Harris County, City of Houston as the site for the performance
of the Project Research.

 

	13.	Severability

 

If any one or more of the provisions
of this Contract shall be held to be invalid, illegal or unenforceable, the validity, legality or enforceability of the remaining
provisions of this Contract shall not in any way be affected or impaired thereby.

 

	14.	Waiver

 

The failure of any party hereto
to insist upon strict performance of any provision of this Contract or to exercise any right hereunder will not constitute a waiver
of that provision or right.

  

    	 	 	 

    
CONFIDENTIAL TREATMENT REQUESTED BY MARKER THERAPEUTICS, INC. 
 
Portions herein identified by [***] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

    

 

	15.	Notices

 

Any notice or communication
required or permitted to be given or made under this Contract by one of the parties hereto to the other shall be in writing and
shall be deemed to have been sufficiently given or made for all purposes if mailed by certified mail, postage prepaid, addressed
to such other party at its respective address as follows:

 

If to the Sponsor:

 

Peter Hoang

President and CEO

Marker Therapeutics, Inc.

3200 Southwest Freeway, Suite 2240

Houston, TX 77027

917-916-6644

 

If to Baylor with respect to all non-technical matters:

 

Michael B. Dilling Ph.D., CLP

Director, Baylor Licensing Group

Baylor College of Medicine

Mail Stop BCM 210

One Baylor Plaza

Houston, Texas 77030-3411

 

If to Baylor with respect to technical questions:

 

(Investigator's name, address,
and phone number)

Dr Juan F Vera

1 Baylor Plaza, MS: BCM505

jfvera@txch.org

832.824.4717

	16.	Assignment

 

This Contract may be assigned
by the Sponsor to any parent, subsidiary, or affiliate of the Sponsor or to any successor in interest only by reason of any merger,
acquisition, partnership, or license agreement only with Baylor's prior written approval which shall not be unreasonably withheld.
Any assignment or attempt to assign, or any delegation or attempt to delegate, in the absence of such prior written consent, shall
be void and without effect. This Contract may not be assigned by Baylor.

 

    	 	 	 

    
CONFIDENTIAL TREATMENT REQUESTED BY MARKER THERAPEUTICS, INC. 
 
Portions herein identified by [***] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

    

 

	17.	Entirety

 

With the exception of the License,
this Contract represents the entire agreement of the parties and it expressly supersedes all previous written and oral communications
between the parties with regard to the Project Research proposed hereunder. No amendment, alteration, or modification of this Contract
or any exhibits attached hereto shall be valid unless executed in writing by authorized signatories of both parties.

 

	18.	Warranties

 

Baylor makes NO WARRANTIES,
EXPRESS OR IMPLIED, CONCERNING THE RESULTS OF THE PROJECT RESEARCH OR OF THE MERCHANTABILITY, OR FITNESS FOR A PARTICULAR PURPOSE
OF SUCH PROJECT RESEARCH OR RESULTS. Baylor shall not be liable for any direct, consequential, or other damages suffered by the
Sponsor or any other party as a result of the conduct of the Project Research. All warranties made or to be made in connection
with the Project Research shall be made by the Sponsor thereof and none of such warranties shall directly or indirectly by implication
obligate in any way Baylor, the Principal Investigator, Baylor's trustees, officers, agents, staff, employees, students, and faculty
members, and its affiliated hospitals.

 

    	 	 	 

    CONFIDENTIAL TREATMENT REQUESTED BY MARKER THERAPEUTICS, INC.  
Portions herein identified by [***] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

    

 

IN WITNESS WHEREOF, the parties hereto have caused this Contract
to be executed in duplicate counterpart original by their duly authorized representatives to be effective as of the Effective Date.

 

	SPONSOR	 	BAYLOR COLLEGE OF MEDICINE
	 	 	 
	By:	/s/ Peter L. Hoang	11/16/18	 	By:	/s/ Michael B. Dilling Ph.D., CLP	11/26/2018
	 	Signature	Date	 	 	Signature	Date
	 	Peter L. Hoang	 	 	Michael B. Dilling Ph.D., CLP
	 	President & CEO	 	 	Director, Baylor Licensing Group

 

 

I acknowledge that I have read this Contract in its entirety
and that I shall use reasonable efforts to uphold my individual obligations and responsibilities set forth herein:

 

	By:	/s/ Juan F. Vera, M.D.	11/21/18	 	By:	/s/ Ann Leen, Ph.D.	11/21/18
	 	Signature	Date	 	 	Signature	Date 
	 	Principal Investigator	 	 	Co-Investigator	 
	 	 	 	 	 	 
	 	Juan F. Vera, M.D.	 	 	Ann Leen, Ph.D.	 
	 	Typed Name	 	 	Typed Name	 
	 	 	 	 	 	 
	 	Principal Investigator	 	 	Co-Investigator	 
	 	Title	 	 	Title	 

 

    	 	 	 

    CONFIDENTIAL TREATMENT REQUESTED BY MARKER THERAPEUTICS, INC.  
Portions herein identified by [***] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

    

 

EXHIBIT A

 

WORKSCOPE

 

[***REDACTED***]

 

Deliverables:

 

[***REDACTED***]

 

Expected
Deliverables:

 

[***REDACTED***] 

 

    	 	 	 

    CONFIDENTIAL TREATMENT REQUESTED BY MARKER THERAPEUTICS, INC.  
Portions herein identified by [***] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

    

 

BUDGET

Salaries and Wages

	Name	% Effort	Year 1	Year 2
	PI	1%	[***REDACTED***]	[***REDACTED***]
	Co-Inv	2%	[***REDACTED***]	[***REDACTED***]
	Postdoc	[***REDACTED***]%	[***REDACTED***]	[***REDACTED***]
	Cell Proc Tech	[***REDACTED***]%	[***REDACTED***]	[***REDACTED***]
	Rsch Tech	[***REDACTED***]%	[***REDACTED***]	[***REDACTED***]
	                 Subtotal:	[***REDACTED***]%	28,971	29,840

 

Fringe Benefits

	Name	% Effort	Year 1	Year 2
	PI	1%	[***REDACTED***]	[***REDACTED***]
	Co-Inv	2%	[***REDACTED***]	[***REDACTED***]
	Postdoc	[***REDACTED***]%	[***REDACTED***]	[***REDACTED***]
	Cell Proc Tech	[***REDACTED***]%	[***REDACTED***]	[***REDACTED***]
	Rsch Tech	[***REDACTED***]%	[***REDACTED***]	[***REDACTED***]
	                 Subtotal:	[***REDACTED***]%	10,406	10,719

 

Supplies (examples below)

	 	Year 1	Year 2
	Tissue Culture	[***REDACTED***]	[***REDACTED***]
	Monoclonal Antibodies	[***REDACTED***]	[***REDACTED***]
	Immune Studies	[***REDACTED***]	[***REDACTED***]
	Cytokines	[***REDACTED***]	[***REDACTED***]
	                     Subtotal:	39,625	40,814

 

	Total Direct Cost for All Year Modular Format	[***REDACTED***]	[***REDACTED***]
	Indirect Cost for regular line items	[***REDACTED***]	[***REDACTED***]
	Total Cost Direct and Indirect per year	[***REDACTED***]	[***REDACTED***]
	Total Budget Requested All Year	 	$256,272

  

    	 	 	 

    CONFIDENTIAL TREATMENT REQUESTED BY MARKER THERAPEUTICS, INC.  
Portions herein identified by [***] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

    

 

Baylor College
of Medicine — Baylor Licensing Group

Monetary Contract Routing Sheet

 

		1.	Contract Type: Sponsored Research Agreement BRAIN 54715-1

 

		2.	Contract Parties: Marker Therapeutics

 

		3.	Contract Principal Investigator: Juan Vera and Ann Leen

 

		4.	Effective Date: 11/16/2018

 

		5.	Contract Term: ending November 15, 2022

 

		6.	Termination without Cause: none

 

		7.	Payment Amount: up to $256,272 (years 1 and 2 only, years 3 and 4 will be covered in an amendment)

 

		(a)	On or before Effective
Date $76,882

 

		(b)	Equal monthly installments
of the remainder $153,764 for two years

 

		8.	%IDC: [***REDACTED***]

  

Principal Investigator Certification: I certify
that I have read the contract and understand the business terms, that the contract is in Baylor's best interest, and that the
activity is consistent with Baylor's mission. 

 

	Signature of Principal Investigator:	/s/
	 	 
	Signature of Department Administrator:	/s/
	 	 
	Signature of Department Chair:	/s/Exhibit 10.38

 

MARKER THERAPEUTICS, INC.

 

CONSULTING SERVICES AGREEMENT

 

This Consulting Services
Agreement (“Agreement”) is hereby made and entered into this 19th day of October, 2018 (“Effective Date”)
by and between Marker Therapeutics, Inc., a Delaware corporation, having an address at 3200 Southwest Freeway, Suite 2240, Houston,
Texas 77027 and its subsidiaries (“Marker” or the “Company”), and Ann Leen, having an address at 2727 Drexel
Drive, Houston, Texas 77027 (“Consultant”). Marker and Consultant are referred to herein collectively as the “Parties”
and individually as a “Party.”

 

WITNESSETH:

 

WHEREAS, Marker
is in need of consulting assistance in the area of a Chief Scientific Officer;

 

WHEREAS, Consultant
has represented that Consultant is qualified to perform and possesses the knowledge to perform those certain services set forth
in this Agreement; and

 

WHEREAS, Marker
desires to engage Consultant as an independent contractor to perform those services set forth herein, and Consultant desires to
accept such engagement.

 

NOW, THEREFORE,
in consideration of the above recitals, which are incorporated herein as covenants, the mutual promises herein made and exchanged
and for other valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows:

 

	1.	Engagement. Marker hereby engages Consultant as an independent contractor to perform consulting
services set forth in this Agreement and in Schedule 1, Consulting Services, which is attached hereto and incorporated
herein by reference (collectively, the “Services” or “Consulting Services”). Consultant hereby accepts
such engagement under the terms set forth herein.

 

	2.	Compensation. Marker shall pay Consultant pursuant to the terms of Schedule 2, Compensation,
attached hereto. Consultant shall be entitled to reimbursement for reasonable expenses, including travel provided that Consultant
submits itemized statements of such expenses in a form acceptable to the Company. All travel within the continental U.S. will be
coach class unless otherwise authorized by an executive officer of the Company. Invoices are subject to review and approval by
Marker and if approved, will be paid no later than 30 days after receipt.

 

	3.	Stock Option Award. Upon execution of the Agreement, Marker will grant Consultant pursuant
to the Company’s 2014 Omnibus Stock Ownership Plan, as amended options to acquire up to 500,000 shares of Marker’s
common stock (the “Options”), in accordance with the terms provided the Stock Option Award Agreement attached as Exhibit
A. The Options shall become vested upon the Consultant’s continued performance of Services under this Agreement for four
years from the date of the grant of the Options with 125,000 shares of the Options vesting on the first anniversary of the date
of grant and the remaining options vesting evenly over the following thirty six (36) months. The Options shall be exercisable at
the closing price of Marker’s common stock as of the date of the grant of such Options.

 

    	 	Page 1 of 11	 

    	 

    

 

	4.	Term and Termination without Cause. The term of this Agreement shall be for twelve (12)
months from the Effective Date and may be renewed by written agreement of the Parties (collectively the “Term”). Either
Party may terminate this Agreement without cause by giving thirty (30) days notice providing written notice to the other Party,
provided that this Agreement shall terminate automatically in the event of the death or disability of Consultant.

 

	5.	Breach, Right to Cure, and Termination for Cause. In the event either Party breaches any
provision of this Agreement, the non-breaching Party may provide written notice of such breach to the breaching Party and the breaching
Party shall have seven (7) days from the date of notice to cure such breach. If such breach is not cured within seven (7) days
from the date of notice, the non-breaching Party may, in addition to any other remedies it may have, immediately terminate this
Agreement by providing written notice to the breaching Party.

 

	6.	Consultant Status. 

 

		6.1	Independent Contractor. Consultant’s relationship with Marker shall be that of an
independent contractor, and Consultant acknowledges and agrees that in performing all Services, Consultant is acting solely as
an independent contractor and not as an employee or agent of Marker and will not by reason of this Agreement or by reason of her
Consulting Services to the Company be entitled to participate in or to receive any benefit or right under any of the Company's
employee benefit or welfare plans. Consultant shall not hold herself out to be an employee or agent of Marker and may use Marker’s
name in her business only with prior written permission by Marker. Except as specifically authorized by the Company, Consultant
shall not enter into any agreements or incur any obligations on behalf of the Company.

 

		6.2	Taxes. Marker shall not be responsible to Consultant or to any governmental agency for the
withholding of federal or state income, social security or other taxes which are customarily imposed upon the salaries of employees.
Consultant acknowledges and agrees that as an independent contractor, Consultant is self-employed and that Consultant alone will
be responsible for federal, state and local taxes, social security withholding, fees, assessments, self-employment taxes, and any
other taxes on any compensation payable to Consultant by Marker under this Agreement (collectively the “Taxes”).

 

    	 	Page 2 of 11	 

    	 

    

 

		6.3	Best Efforts. It is recognized that Consultant is not obligated to devote all of her time,
energy and skill to the business interests of Marker but, at the same time, Consultant: (i) shall refrain from any other activity
(for herself or any other company) that would compete with or conflict with the activities of Marker related to the generation
and/or commercialization of T cells targeting non-viral tumor-associated antigens and/or cancer testis antigens; (ii) shall not
engage in any other endeavor which would unreasonably interfere with Consultant’s obligations under this Agreement; and (iii)
shall devote such time as may be necessary for the performance of the Services. The Parties acknowledge that Consultant is employed
by Baylor College of Medicine, a Texas non-profit corporation (“Baylor”) and Marker has an exclusive license agreement
with Baylor (the “License Agreement”).

 

		6.4	Non-Solicitation. During the Term of this Agreement and for a period of one (1) year subsequent
to the termination or expiration of this Agreement, Consultant shall not, without the prior written consent of Marker, directly,
indirectly, or through any other party solicit employees of Marker for employment by Consultant.

 

		6.5	Non-Competition. During the Term of this Agreement and for a period of one (1) year subsequent
to the termination or expiration of this Agreement, Consultant shall not, within the United States of America: (i) engage in any
employment, business, or activity or provide services to any third party that is in any way competitive with the business or activities
of Marker related to the generation and/or commercialization of T cells targeting non-viral tumor-associated antigens and/or cancer
testis antigens, or (ii) assist any other person or organization in competing with Marker or engaging in competition with the business
or activities of Marker related to the generation and/or commercialization of T cells targeting non-viral tumor-associated antigens
and/or cancer testis antigens. For the avoidance of doubt business or activities related to the generation and/or commercialization
of T cells targeting neo-epitopes are excluded from this agreement.

 

	7.	Release and Indemnification. Consultant shall be solely liable for any loss or damage to
any person or property caused by the actions or omissions of Consultant. Consultant hereby waives, releases, discharges and indemnifies
Marker and its employees, directors, officers and agents and holds the same harmless from and against, and Consultant assumes full
responsibility for: (i) any and all liabilities, costs, actions, demands or damages whatsoever, including attorneys’ costs
and fees, with respect to or relating to any injury, sickness, harm or damage incurred by the Consultant that is related to this
Agreement or the performance of the Services; (ii) injuries to persons, or damages to property, including theft, related to or
resulting from Consultant’s acts or omissions; (iii) the payment of any Taxes, including any fines, interest or penalties
associated, imposed or required with respect to this Agreement; and (iv) any liabilities, claims, and liens of Consultant.

 

	8.	Confidential Information and Rights to Materials.

 

		8.1	Definitions.

 

		8.1.1	The term “Company Documentation” shall mean notes, memoranda, reports, lists, records,
drawings, sketches, designs, specifications, software programs, books, files, forms, papers, accounts, data, documentation and
other materials of any nature and in any form, whether written, printed or in digital format or otherwise, whether prepared or
paid for by Consultant or anyone else relating to any matter related to the performance of the Services, the scope of the business
of Marker, or Marker’s dealings or affairs.

 

    	 	Page 3 of 11	 

    	 

    

 

		8.1.2	The term “Confidential Information” shall mean any information concerning the organization,
business or finances of Marker or of any third party which Marker is under an obligation to keep confidential that is maintained
by Marker as confidential. Such Confidential Information shall include, but is not limited to, trade secrets or confidential information
respecting patient or research participant lists, patient records, procedures, business plans and strategies, projects, plans,
proposals, research and development, inventions, products, designs, market research data or analyses, technical information, marketing
activities and procedures, methods, know-how, techniques, systems, processes, credit, financial and other data concerning Marker.
For purposes of this Agreement, Confidential Information shall not include any information: (i) that is publicly available at the
time of disclosure; (ii) that is or becomes generally known to the public through no fault of the Consultant; (iii) that is obtained
without restriction from an independent source having a bona fide right to use and disclose such information, without restriction
as to further use or disclosure; (iv) that Marker approves in advance in writing for unrestricted release; or (v) that is required
to be disclosed by law, provided that written notice of the intent to disclose based on such reason is provided to Marker by Consultant
seven (7) days prior to the scheduled date of disclosure.

 

		8.1.3	The term “Proprietary Rights and Inventions” shall mean any and all rights and materials,
including, but not limited to, patentable or non-patentable inventions, discoveries, concepts, ideas, techniques, methods (excluding
published or standard methods dedicated to the public), apparatus, formulas, trademark and service mark rights, patent rights,
trade secret rights and all other proprietary rights, as well as improvements thereof, generated by, made or conceived by, or arising
out of the efforts of Consultant, either solely or jointly with others, whether patentable or not and whether or not reduced to
practice, while: (i) acting in furtherance of this Agreement, which includes performing the Services; or (ii) utilizing Marker’s
facilities, personnel or materials. Proprietary Rights and Inventions shall be deemed Confidential Information. The Consultant
has informed Marker, in writing, of any and all inventions which he claims as her own or otherwise intends to exclude from this
Agreement because it was developed by her prior to the Effective Date. The Consultant acknowledges that after execution of this
Agreement he shall have no right to exclude any Proprietary Rights and Inventions from this Agreement. Consultant shall make and
maintain adequate and current written records of all Proprietary Rights and Inventions, and shall disclose all Proprietary Rights
and Inventions promptly, fully and in writing to the Company immediately upon development of the same and at any time upon request.

 

    	 	Page 4 of 11	 

    	 

    

 

		8.2	Nondisclosure. Consultant acknowledges that Marker’s Confidential Information is valuable,
special and a unique asset of Marker, and that Consultant may, whether or not intentionally, gain access to and knowledge of the
Confidential Information during Consultant’s performance under this Agreement. In light of the highly competitive nature
of the industry in which Marker’s business is conducted, Consultant shall not reveal to any person or entity any Confidential
Information, except as authorized by Marker in writing, and shall keep secret all matters entrusted to Consultant and shall not
use or attempt to use any Confidential Information, except as may be required in the course of performing the Services under this
Agreement, nor shall Consultant directly or indirectly use any Confidential Information in any manner that may injure or cause
loss or may be calculated to injure or cause loss to Marker. The obligations of confidentiality and nonuse shall survive for ten
(10) years from the expiration or termination of this Agreement, whichever occurs first. Furthermore, Consultant shall not make,
use or permit to be used any Company Documentation otherwise than for the benefit of Marker, whether during the Term or after the
termination or conclusion of this Agreement. All Company Documentation shall be and remain the sole and exclusive property of Marker.
Immediately upon the termination or conclusion of this Agreement, Consultant shall immediately deliver all Company Documentation
in her possession, and all copies thereof, to Marker.

 

		8.3	Conveyance. Consultant hereby conveys, assigns, transfers and delivers to Marker, and agrees
to convey, assign, transfer and deliver to Marker, all Proprietary Rights and Inventions, as well as Consultant’s right,
title and interest in and to any Proprietary Rights and Inventions, if any. Consultant shall not, at any time or in any manner,
challenge Marker’s ownership of such Proprietary Rights and Inventions. Consultant shall assist Marker or its representatives,
at the expense of Marker, to obtain, maintain and enforce any United States and foreign letters patent for any Proprietary Rights
and Inventions, that Marker may elect and shall execute, acknowledge and confirm in writing the complete ownership by Marker of
the Proprietary Rights and Inventions, as requested by Marker from time to time. Consultant also agrees to execute an unconditional
assignment to Marker of Consultant’s right, title and interest in the Proprietary Rights and Inventions. In the event that
the above provisions requiring Consultant’s execution of an assignment to Marker is found invalid or void, Consultant agrees
that Marker shall have a non-exclusive, royalty-free, perpetual license to make, use, sell or exploit such Proprietary Rights and
Inventions. The Parties acknowledge the work Consultant performs for Baylor is subject to obligations Consultant has to Baylor,
including as to work done at Baylor that would be part of the License Agreement.

 

    	 	Page 5 of 11	 

    	 

    

 

		8.4	Remedies. Consultant acknowledges and agrees that Marker’s remedy at law for a breach
or threatened breach of any of the provisions of Section 7 would be inadequate and the breach shall be per se deemed as causing
irreparable harm to Marker. Therefore, in the event of a breach by Consultant of any of the provisions of Section 7, Consultant
agrees that, in addition to any remedy at law available to Marker, including, but not limited to, monetary damages, Marker, without
posting any bond, shall be entitled to obtain, and Consultant agrees not to oppose Marker’s request for equitable relief
in the form of specific performance, temporary restraining order, temporary or permanent injunction, or any other equitable remedy
which may then be available to Marker. Nothing in this Agreement shall be construed as prohibiting Marker from pursuing any other
remedies available to it for such breach or threatened breach.

 

		8.5	Consultants’ Third-Party Confidential Information. During the Term of this Agreement,
Consultant will not improperly disclose to Marker or use in the conduct of the Services any proprietary or confidential information
or trade secrets of any former employer or other third party to which Consultant owes a duty of confidentiality with respect to
same, and that Consultant will not bring onto the premises of Marker any proprietary information belonging to a third party unless
consented to in writing by such third party.

 

		8.6	Return of property. The Consultant agrees that all originals and all copies of materials
containing, representing, evidencing, recording, or constituting any Confidential Information, however and whenever produced (whether
by the Consultant or others), shall be the sole property of the Company.

 

At any time upon request of the
Company, the Consultant shall return promptly any and all Confidential Information, including customer or prospective customer
lists, other customer or prospective customer information or related materials, computer programs, software, electronic data, specifications,
drawings, blueprints, medical devices, samples, reproductions, sketches, notes, notebooks, memoranda, reports, records, proposals,
business plans, or copies of them, other documents or materials, tools, equipment, or other property belonging to the Company or
its customers which the Consultant may then possess or have under her control.

 

The Consultant further agrees that
upon termination of her engagement she shall not take with her any documents or data in any form or of any description containing
or pertaining to Confidential Information or any Inventions.

 

	9.	Binding. This Agreement shall be binding upon the Parties and their respective successors
and permitted assigns.

 

    	 	Page 6 of 11	 

    	 

    

 

	10.	Modification and Severability. This Agreement may not be modified orally. Modification to
this Agreement may be made from time to time, provided that such modification is in writing, attached as an addendum to this Agreement
and signed by both Parties. In the event any provision of this Agreement or any part thereof is held invalid or unenforceable,
the validity and enforceability of the remaining portions of the Agreement shall not be affected.

 

	11.	Notice. Any notice, demand, payment, or communication required, permitted, or desired to
be given in relation to this Agreement shall be deemed effectively given when personally delivered; when received by overnight
courier; or five (5) days after being deposited in the United States mail, and sent first class with postage prepaid thereon, certified
and return receipt requested, addressed as follows:

 

	 	Consultant:	Ann Leen
	 	 	2727 Drexel Drive
	 	 	Houston, Texas 77027
	 	 	 
	 	Marker:	Marker Therapeutics, Inc.
	 	 	Attention: Chief Executive Officer
	 	 	3200 Southwest Freeway, Suite 2240
	 	 	Houston, Texas 77027
	 	 	 
	 	With a copy to:	Shumaker, Loop & Kendrick, LLP
	 	 	Attention:  Mark A. Catchur
	 	 	101 E. Kennedy Boulevard
	 	 	Suite 2800
	 	 	Tampa, Florida 33602

 

	12.	Survival. The provisions of Sections 6, 7, 8, and 14 shall survive termination or expiration
of this Agreement.

 

	13.	Force Majeure. In the event Consultant shall be delayed or hindered in or prevented from
the performance of any act required hereunder by reasons of strike, lockouts, labor troubles, inability to procure materials, failure
of power or restrictive government or judicial orders or decrees, riots, insurrection, war, Acts of God, or any other reason or
cause beyond Consultant's reasonable control, then performance of such act shall be excused for the reasonable period of such delay.

 

	14.	Governing Law. This Agreement has been entered into in the State of Texas and shall be governed
by, construed and interpreted in accordance with the laws of the State of Texas without reference to conflict of laws principles
or statutory rules of arbitration included therein. Any dispute and proceeding under this Agreement shall be subject to the exclusive
jurisdiction and venue of the state and federal courts located in Harris County, Texas, and the Parties hereby consent to the exclusive
personal jurisdiction and venue of these courts.

 

	15.	Non-Waiver. The failure of either Party to insist upon the strict performance of any term
of this Agreement shall not constitute a waiver of such term or a waiver of the right to assert a breach thereof. No waiver of
any breach shall alter or affect this Agreement, which shall continue in full force and effect until its expiration or termination.

 

    	 	Page 7 of 11	 

    	 

    

 

	16.	Enforcement. The prevailing Party shall be entitled to collect from the other Party all
reasonable fees, costs and expenses including attorneys’ fees and costs incurred by the prevailing Party in connection with:
(i) the enforcement of any available remedy for breach of this Agreement; or (ii) any dispute arising from or related to this Agreement
or the relationship between the Parties.

 

	17.	Entire Agreement. This Agreement constitutes the entire understanding between the Parties
and contains all the understandings between the Parties with respect to the subject matter hereof; this Agreement supersedes any
and all other understandings, either oral or written, between the Parties with respect to the subject matter hereto.

 

	18.	Assignment. This Agreement shall be binding upon and inure to the benefit of the parties
hereto and their respective successors and permitted assigns. This Agreement is not intended to confer upon any person other than
the parties hereto any rights or remedies hereunder, except as otherwise expressly herein and shall not be assignable by operation
of law or otherwise.

 

	19.	Protected Health Information. In the event that the Consultant requests or needs protected
health information as defined under the Health Insurance Portability and Accountability Act of 1996 ("HIPAA") in order
to perform the Services, then if permitted by law, Marker shall transfer the protected health information under a separate agreement
(e.g. Business Associate Agreement).

 

	20.	Marker Premises. Consultant will abide by all laws, rules and regulations that apply to
the performance of the Services and, when on Marker’s premises, will comply with Marker’s policies, procedures and
standards with respect to conduct of visitors as made known to Consultant.

 

 

[Signature page to follow]

 

    	 	Page 8 of 11	 

    	 

    

 

 

IN WITNESS WHEREOF, the Parties
have executed this Agreement on the Effective Date.

 

Marker Therapeutics, Inc.

  

	By:	/s/Peter Hoang	 
	 	Peter Hoang	 
	 	Chief Executive Officer	 

  

 

	/s/Ann Leen	 
	Ann Leen	 

 

    	 	Page 9 of 11	 

    	 

    

 

SCHEDULE 1

 

CONSULTING SERVICES

 

 

(a)              
Scope. Company hereby retains Consultant, and Consultant hereby agrees to be retained by Company as its Chief
Scientific Officer.

 

(b)              
Duties. During the term of this Agreement, Consultant shall be reasonably available to Marker via e-mail,
telephone or in person to Marker for consulting services as its Chief Scientific Officer and perform the duties typically assigned
to the chief scientific officer of a similarly situated company in the Company’s industry. The Consultant shall also perform
such other reasonable duties as may hereafter be requested of her by the Chief Executive Officer, consistent with the services
and providing such further services to the Company as may reasonably be requested of her. Such consulting services as requested
from time to time by Marker may include, but not be limited to, subject matter related to Marker’s technologies under development,
ongoing clinical studies, scientific research and other activities that are within the scope of duties of a Chief Scientific Officer.
The Consultant will report to the Chief Executive Officer of the Company, and carry out the decisions and otherwise abide by and
enforce the rules and policies of the Company.

 

(c)              
Performance and Time Commitment. The Consultant agrees to be available to render the Consulting Services
as requested.

 

(d)              
Professional Standards. The Consultant agrees to devote her best efforts to performing the Consulting Services.
The Consultant shall comply with all rules, procedures and standards promulgated from time to time by the Company with regard
to the Consultant's access to and use of the Company's property, information, equipment and facilities.

  

    	 	Page 10 of 11	 

    	 

    

 

SCHEDULE
2

 

 COMPENSATION

 

The Compensation payable to Consultant
shall consist of the following:

 

		1.	Annual Cash Consulting Fee. Marker will pay Consultant a base consulting fee of $350,000.00
in cash per year (“Base Consulting Fee”). The Consultant’s base consulting fee shall be paid in approximately
equal bi-weekly installments in accordance with the Company’s customary payroll practices.

 

		2.	Discretionary Cash Payment. For each calendar year during the term of this Agreement, Consultant
shall be eligible to receive a discretionary cash payment of a maximum of 35% of Consultant’s Base Consulting Fee based on
Consultant’s services and commitment to Marker, prorated for partial years, to be paid within a reasonable time after the
end of the applicable fiscal year of the Company, but in no event later than five days after the completion of the audit for the
prior year it being understood that the Board of Directors of Marker may in its discretion pay such bonus earlier.

 

    	 	Page 11 of 11

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00293-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00293-of-00352.parquet"}]]